we know that its one of the best hospital drugs and they sold aprox 2.8 billion in US and Novartis/Sandoz/MNTA have about 1 billion annualized sales so far of which MNTA gets to keep about 45% after all expenses are deducted. Compare that number to 45 million shares and think about it for a minute. Even if MNTA gets a net of 200-250 million after all the expenses its about 3 to 4 to possibly 5 per share in earnings. Lets say 4 in earnings for Lovenox and once Copaxone starts double it to another 4-5 in earnings.
You want people to believe that now that MNTA benefits - the margins are much smaller than when Sanofi sold it?
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
